Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
Abeona Therapeutics (ABEO) Stock Price & Analysis
1,186 Followers
ABEO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.19 - $9.35
Previous Close$2.78
Volume1.47K
Average Volume (3M)199.12K
Market Cap
$46.55M
Enterprise Value$36.85M
Total Cash (Recent Filing)$18.17M
Total Debt (Recent Filing)$8.29M
Price to Earnings (P/E)-0.2
Beta1.47
Next Earnings
May 12, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.64
Shares Outstanding17,175,799
10 Day Avg. Volume140,926
30 Day Avg. Volume199,119
Standard Deviation0.25
R-Squared0.07
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)3.02
Price to Sales (P/S)35.48
Price to Cash Flow (P/CF)30.00
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.48
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Abeona Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABEO FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was $2.19 and its highest was $9.35 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Currently, no data Available
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is May 12, 2023 which is in 44 days.
How were Abeona Therapeutics’s earnings last quarter?
Currently, no data Available
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Overvalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 17,175,798 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Abeona Therapeutics?
Among the largest hedge funds holding Abeona Therapeutics’s share is Deerfield Management Company, LP. It holds Abeona Therapeutics’s shares valued at 3M.
---
Abeona Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Increased
By 869.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.31%
12-Months-Change
Fundamentals
Return on Equity
-179.18%
Trailing 12-Months
Asset Growth
-67.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Abeona Therapeutics
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
---
Top 5 ETFs holding ABEO
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold ABEO. The ETFs are listed according to market value of ABEO within the ETF
---
Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.
Xilio Therapeutics
―
Adverum Biotechnologies
―
Axcella Health
―
Magenta Therapeutics
―
---